Physician
Epmed, PA
Epmed, PA was paid $9.32M by Medicaid between Jan 2018 and Dec 2024, across 105 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 35% of everything it billed.
33Billing provider infoEPMED, PA
EL PASO, TX 79903
EL PASO, TX 79903
33aNPI1285861773assigned 06/11/2009
33bProvider typePain Medicine (Anesthesiology) Physician
28Total paid$9.32M
24GClaims311,416
24DCodes billed105
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pain Medicine (Anesthesiology) Physician providers in Texas
Rank by total paid#2 of 64
Median peer was paid$7K
This provider vs. median1,423×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 25,195 | $954K | |
| 2019 | 26,409 | $953K | |
| 2020 | 29,915 | $870K | |
| 2021 | 62,442 | $1.49M | |
| 2022 | 66,415 | $1.62M | |
| 2023 | 54,123 | $1.69M | |
| 2024incomplete | 46,917 | $1.74M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 35% | 62,492 | 56,960 | $3.31M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 15% | 30,161 | 28,485 | $1.37M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 11% | 7,857 | 7,311 | $1.03M |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 4.4% | 4,411 | 4,135 | $409K |
| G0659 | Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem), excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase), performed without method or drug-specific calibration, without matrix-matched quality control material, or without use of stable isotope or other universally recognized internal standard(s) for each drug, drug metabolite or drug class per specimen; qualitative or quantitative, all sources, includes specimen validity testing, per day, any number of drug classes | 3.6% | 6,194 | 6,166 | $335K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 3.0% | 3,172 | 3,063 | $283K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 3.0% | 2,260 | 2,158 | $281K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 2.3% | 8,939 | 8,669 | $211K |
| 64483 | 2.1% | 1,313 | 1,103 | $198K | |
| 77002 | 1.4% | 3,707 | 3,044 | $132K | |
| 80050 | General health panel | 1.3% | 2,947 | 2,771 | $126K |
| 82607 | 1.2% | 8,966 | 8,697 | $108K |
93 more codes
| 82746 | 1.1% | 8,522 | $100K | |
| 82728 | <1% | 6,779 | $78K | |
| 64493 | <1% | 526 | $75K | |
| 80053 | Comprehensive metabolic panel | <1% | 8,138 | $67K |
| 83735 | <1% | 12,398 | $67K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,325 | $66K |
| 99441 | <1% | 1,606 | $66K | |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 414 | $64K |
| 20610 | <1% | 2,273 | $64K | |
| 83550 | <1% | 6,537 | $48K | |
| 82550 | <1% | 8,535 | $45K | |
| 84100 | <1% | 11,874 | $43K | |
| 84550 | <1% | 11,650 | $42K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 6,344 | $38K |
| 83540 | <1% | 6,719 | $37K | |
| 83992 | <1% | 2,860 | $36K | |
| 80305 | <1% | 3,458 | $34K | |
| 80356 | <1% | 2,852 | $34K | |
| 64494 | <1% | 466 | $34K | |
| 99443 | <1% | 693 | $31K | |
| 80324 | <1% | 2,669 | $30K | |
| 80353 | <1% | 2,680 | $25K | |
| 80361 | <1% | 1,871 | $24K | |
| 20553 | <1% | 568 | $23K | |
| 80348 | <1% | 1,683 | $22K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 9,636 | $22K |
| 80359 | <1% | 2,854 | $22K | |
| 80354 | <1% | 1,771 | $21K | |
| 80365 | <1% | 1,786 | $19K | |
| 99442 | <1% | 385 | $19K | |
| 80362 | <1% | 1,772 | $19K | |
| 80372 | <1% | 1,771 | $17K | |
| 80373 | <1% | 1,815 | $17K | |
| 80358 | <1% | 1,699 | $17K | |
| 80355 | <1% | 2,159 | $16K | |
| 80366 | <1% | 2,092 | $14K | |
| CP004 | <1% | 1,470 | $13K | |
| 64484 | <1% | 148 | $13K | |
| 80306 | <1% | 814 | $12K | |
| 64495 | <1% | 119 | $10K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 16,264 | $10K |
| 62323 | <1% | 66 | $9K | |
| 81226 | <1% | 16 | $6K | |
| 80346 | <1% | 436 | $6K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 446 | $5K |
| 64635 | <1% | 13 | $4K | |
| 27096 | <1% | 43 | $4K | |
| 81225 | <1% | 16 | $4K | |
| 80336 | <1% | 205 | $3K | |
| 81401 | <1% | 28 | $3K | |
| 80360 | <1% | 304 | $3K | |
| 80345 | <1% | 300 | $3K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 376 | $2K |
| 81227 | <1% | 16 | $2K | |
| 64636 | <1% | 15 | $2K | |
| 86003 | <1% | 12 | $2K | |
| 85027 | <1% | 202 | $1K | |
| 82530 | <1% | 99 | $1K | |
| 81355 | <1% | 16 | $1K | |
| 81241 | <1% | 16 | $1K | |
| 81240 | <1% | 16 | $926.25 | |
| 81291 | <1% | 16 | $921.30 | |
| 81400 | <1% | 16 | $781.56 | |
| 80335 | <1% | 93 | $378.00 | |
| 84403 | <1% | 12 | $353.06 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 445 | $337.84 |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 13 | $316.27 |
| 84681 | <1% | 12 | $289.92 | |
| 86225 | <1% | 17 | $201.90 | |
| 86200 | <1% | 17 | $185.25 | |
| 86431 | <1% | 16 | $162.19 | |
| 83525 | <1% | 12 | $159.12 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 219 | $130.89 |
| 86140 | <1% | 16 | $74.09 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 348 | $65.22 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 28 | $64.01 |
| 85651 | <1% | 16 | $53.24 | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | <1% | 571 | $0.69 |
| G8431 | Screening for depression is documented as being positive and a follow-up plan is documented | <1% | 311 | $0.38 |
| G8950 | Elevated or hypertensive blood pressure reading documented, and the indicated follow-up is documented | 0% | 227 | $0.00 |
| 1036F | 0% | 482 | $0.00 | |
| J2704 | Injection, propofol, 10 mg | 0% | 48 | $0.00 |
| G8420 | Bmi is documented within normal parameters and no follow-up plan is required | 0% | 213 | $0.00 |
| G8754 | Most recent diastolic blood pressure < 90 mmhg | 0% | 170 | $0.00 |
| G8752 | Most recent systolic blood pressure < 140 mmhg | 0% | 111 | $0.00 |
| 1124F | 0% | 339 | $0.00 | |
| G8730 | Pain assessment documented as positive using a standardized tool and a follow-up plan is documented | 0% | 568 | $0.00 |
| G9622 | Patient not identified as an unhealthy alcohol user when screened for unhealthy alcohol use using a systematic screening method | 0% | 579 | $0.00 |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 321 | $0.00 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 600 | $0.00 |
| G8783 | Normal blood pressure reading documented, follow-up not required | 0% | 415 | $0.00 |
| G8753 | Most recent systolic blood pressure >= 140 mmhg | 0% | 43 | $0.00 |
| 4004F | 0% | 67 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialVAZQUEZ, EDUARDO (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Gateway Surgical Center, LLC | El Paso, TX | $143K |
| Epmed, PA | El Paso, TX | $141K |
| Epmed, PA | Las Cruces, NM | $46K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.